See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Alix Ventures supports early-stage Life Science startups engineering biology to drive radical advances in human health. The firm is focused on the rise of 'TechBio' — companies melding technology and biology — which it believes is leading to some of the most impactful healthcare solutions in decades. Alix partners with passionate, accomplished founders who possess unique insights to solve daring problems in Life Sciences, with particular interest in platforms for 'Novel Applications' (Therapeutics/Diagnostics) and 'Bio-Economy Infrastructure' (Tools/Services/Manufacturing), including Drug Development Infrastructure, Tech-Enabled Diagnostics, Genomic Data Platforms, Gene Editing, and Lab Automation. The firm explicitly does not invest in companies outside the USA, single-asset therapeutics, medical devices, or AgTech.
Notable quotes
“Successful companies take many years to build, so we look for Founders we could see ourselves working with for 10+ years. We like Founders that embody Wizardry, Scar Tissue, Wave Generator, Micro Macro, Liaison, Eye of the Storm, and Always be Chasing — the best Founders are determined, passionate, grounded, smart, creative, and can get right back up after getting knocked down.”
“One company, founded by one person, born from one idea can truly change the world. As irrational as it sounds, we live in the time where radical change is possible and happens often. Every day, history somewhere is being made. To those with a dream, I say, 'grab your slingshots!'”
“No great feat has ever been accomplished in isolation, it truly takes a village — always lend a helping hand to others as they will help you along the journey.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| iOrganBio (Aether Biomachines) | Seed | — | 2025-10 |
| Zafrens | Series A | — | 2025-02 |
| Elegen | Series B | $35m | 2024-05 |
| Chemify | Series A | $43m | 2023-08 |
| Xilis | Series A | $89m | 2022-07 |
| Endpoint Health | Series A | $52m | 2022-06 |
| Mythic Therapeutics | Series B | — | — |
| Circularis | Seed | — | — |
| Teiko Bio | Seed | — | — |
| Pair Team | Seed | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Triatomic Capital | 2 |
| 8VC | 2 |
| Andreessen Horowitz (a16z) | 2 |
| Mubadala Capital | 1 |
| Felicis Ventures | 1 |
| Mayfield Fund | 1 |
Fit check
Is Alix Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit